ClinicalTrials.gg
CompletedNCT05842876Updated Mar 10, 2025

Happy Baby Hearts Study

An observational study in Coarctation of Aorta, sponsored by University of Wisconsin, Madison. Completed at 2 sites in United States. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by University of Wisconsin, Madison · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
82
Ages
15 Years and older
Sex
All
01

Study summary

The goal of this observational study is to determine the feasibility of renal Near Infrared Spectroscopy (NIRS) monitoring in the newborn nursery for newborns at low risk of coarctation of the aorta (CoA). The main questions it aims to answer are:

  • whether continuous renal NIRS monitoring is feasible;
  • whether NIRS monitoring results in higher nursing and parent/caregiver satisfaction than current standard monitoring; and,
  • whether participants who develop CoA will spend a smaller proportion of time within the normal range than patients who do not have CoA.

Participants will be observed through continuous renal oxygenation monitoring with NIRS.

02

Conditions studied

  • Coarctation of Aorta

Browse trials for

03

In context

Aortic Coarctation

49 studies on the registry are indexed under Aortic Coarctation; 16 are open to participants now.

This study's enrollment of 82 is below the median of 100 across 29 observational studies indexed under Aortic Coarctation.

Browse Aortic Coarctation studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

  1. Neonates admitted to the nursery or NICU at Meriter Hospital, Inc. or UWHealth Kids - American Family Children's Hospital (AFCH) who are ≥ 35 weeks' gestation and have a prenatally identified concern for coarctation of the aorta.
  2. Primary parent/guardian of neonate.
  3. Nursing staff at Meriter Hospital, Inc.'s Newborn Nursery

Eligibility criteria

Neonate Inclusion Criteria:

  • Delivered at ≥ 35 weeks of gestation
  • \<12 hours of age
  • Inpatient at Meriter Hospital, Inc. NICU or Newborn Nursery or AFCH PICU or NICU
  • Diagnosed as at risk for CoA

Neonate Exclusion Criteria:

  • Major congenital anomalies of the kidney
  • Attending physician's discretion to not place sensors due to clinical concerns
  • In the researcher's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life

Primary Caregiver Inclusion Criteria:

  • Able to understand and the willing to sign a written document
  • Willing to comply with all study procedures and be available for the duration of the study
  • Birth parent (i.e., the parent who gave birth to the baby) who is the primary caregiver of a neonate who is eligible to participate in study
  • Agrees to enroll neonate into study
  • Aged 15 years or older
  • Pregnant mother with a baby diagnosed prenatally as at risk for CoA will be eligible for the study. They must also meet the following criteria:
  • Require an "arch watch care plan" as a results of prenatal ultrasonography findings
  • Agree to enroll offspring into the study at birth

Primary Caregiver Exclusion Criteria:

  • Subject is unable to provide informed consent, including subjects who are in foster care and subjects within state custody
  • Pregnant woman who does not plan to maintain custody of the child after birth, such as instances of adoption or surrogacy

Newborn Nursery Nursing Staff:

  • All Newborn Nursery nursing staff at Meriter Hospital, Inc.'s Newborn Nursery are eligible to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
82 participants (actual)
Patient registry
No

Groups and cohorts

  • Caregiver + Low Risk neonates

    Participants in the nursery who are expected to be lower risk for CoA

    Device: Continuous Renal NIRS Monitoring · Diagnostic Test: Standard Clinical Care · Other: Satisfaction Survey

  • Caregiver + Medium to High Risk neonates

    Participants in the NICU who are expected to be at a higher risk for CoA

    Diagnostic Test: Standard Clinical Care

  • Nurses in the Newborn Nursery

    Nurses who work at the Meriter Hospital, Inc. Newborn Nursery

    Other: Satisfaction Survey

Interventions

  • DeviceContinuous Renal NIRS Monitoring

    Renal oxygenation data collected every 6 seconds

  • Diagnostic testStandard Clinical Care

    q6 h BP, q6 h Pulse ox, Echo at 24-72h

  • Diagnostic testStandard Clinical Care

    Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h

  • OtherSatisfaction Survey

    Survey to assess which method of monitoring is preferred

06

What researchers measure

Primary outcomes

  1. Percent of time monitored

    Amount of time continuously monitored will be calculated

    Time frame: Up to 2 weeks post-delivery, on average

  2. Count of adverse and unexpected events

    All adverse and unexpected events will be recorded

    Time frame: Up to 2 weeks post-delivery

Secondary outcomes

  1. Change in nursing satisfaction with renal NIRS monitoring

    A subjective description of survey responses in addition to determining which method of monitoring is preferred: NIRS vs. Enhanced BP/Pulse ox checks. Survey will be conducted at the beginning of the study, and one year later.

    Time frame: Study start to one year later

  2. Parent/caregiver satisfaction with renal NIRS monitoring

    A subjective description of survey responses in addition to determining which method of monitoring is preferred: NIRS vs. Enhanced BP/Pulse ox checks

    Time frame: Up to 2 weeks post-delivery, on average

  3. Renal oxygen trends

    A permutation test will be used to compare the distribution of proportions (of time spent within normal range) between the two groups (CoA vs. normal)

    Time frame: Through study completion, approximately 1 year

07

Study locations

2 sites
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
  • Meriter Hospital, Inc.
    Madison, Wisconsin 53715, United States
08

References and documents

Publications

  • Singh Y. Evaluation of a child with suspected congenital heart disease. Paediatrics and Child Health 2018, 28(12): 556-561
  • Levey A, Glickstein JS, Kleinman CS, Levasseur SM, Chen J, Gersony WM, Williams IA. The impact of prenatal diagnosis of complex congenital heart disease on neonatal outcomes. Pediatr Cardiol. 2010 Jul;31(5):587-97. doi: 10.1007/s00246-010-9648-2. Epub 2010 Feb 18. PubMed 20165844 ↗
  • Gomez-Montes E, Herraiz Garcia I, Escribano Abad D, Rodriguez Calvo J, Villalain Gonzalez C, Galindo Izquierdo A. Application of a Global Multiparameter Scoring System for the Prenatal Prediction of Coarctation of the Aorta. J Clin Med. 2021 Aug 20;10(16):3690. doi: 10.3390/jcm10163690. PubMed 34441986 ↗
  • Maskatia SA, Kwiatkowski D, Bhombal S, Davis AS, McElhinney DB, Tacy TA, Algaze C, Blumenfeld Y, Quirin A, Punn R. A Fetal Risk Stratification Pathway for Neonatal Aortic Coarctation Reduces Medical Exposure. J Pediatr. 2021 Oct;237:102-108.e3. doi: 10.1016/j.jpeds.2021.06.047. Epub 2021 Jun 26. PubMed 34181988 ↗
  • Korcek P, Stranak Z, Sirc J, Naulaers G. The role of near-infrared spectroscopy monitoring in preterm infants. J Perinatol. 2017 Oct;37(10):1070-1077. doi: 10.1038/jp.2017.60. Epub 2017 May 4. PubMed 28471443 ↗
  • Hazle MA, Gajarski RJ, Aiyagari R, Yu S, Abraham A, Donohue J, Blatt NB. Urinary biomarkers and renal near-infrared spectroscopy predict intensive care unit outcomes after cardiac surgery in infants younger than 6 months of age. J Thorac Cardiovasc Surg. 2013 Oct;146(4):861-867.e1. doi: 10.1016/j.jtcvs.2012.12.012. Epub 2013 Jan 12. PubMed 23317940 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jan 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2023
First posted
May 6, 2023
StartActual
Apr 19, 2023
Primary completionActual
Jan 21, 2025
CompletionActual
Jan 21, 2025
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05842876
Collaborators
Meriter Foundation
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Apr 19, 2023
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Last update
Mar 10, 2025

Study contacts

Matthew Harer, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion